 |
BMY
Todays recommendations include $BMY and $DBTK, to find out more sign up for the Free Daily Newsletter from the... http://bit.ly/ckd39a
BMY
$BMY (Bristol-Myers Squibb) $24.23 crossed its 1st Pivot Point Resistance #emppv #stocks
http://empirasign.com/l/tx2d.htm
BMY
Continue to think $MJD could be acquisition target. Recently spun off by $BMY in tax advantaged structure. Potential set up for a sale $$
BMY
Stopped out of $BMY, $JCG, $GS, and $WLT. Today is like an entire reset to my portfolio!
BMY
RT @mhuckman Blogging about "Cherish Bio Sciences" and revealing my own "corporate secret." $BMY http://bit.ly/ahpm9G
BMY
Blogging about "Cherish Bio Sciences" and revealing my own "corporate secret." $BMY http://bit.ly/ahpm9G
BMY
RT @mhuckman: US Atty says guy worked in Bristol tech ops & stole "numerous trade secrets" from '07 until he was fired yesterd
BMY
RT @adamfeuerstein: My story on $ALKS and its 1x/ mo. version of $BMY's Abilify. http://bit.ly/cyv92V hey @popsalks, what do you think?
BMY
RT @adamfeuerstein: My story on $ALKS and its 1x/ mo. version of $BMY's Abilify. http://bit.ly/cyv92V hey @popsalks, what do you think?
BMY
My story on $ALKS and its 1x/ mo. version of $BMY's Abilify. http://bit.ly/cyv92V hey @popsalks, what do you think?
BMY
Alkermes $ALKS PR on very early-stage development for potential 1x/mo version of Bristol's Abilify. $BMY http://tinyurl.com/pmalksabil
BMY
Cherish JAIL Time, Boy RT @mhuckman Bristol $BMY guy charged w/stealing co secrets was.. planning to start a drug, "Cherish Bio Science
BMY
RT @mhuckman: Reading feds' criminal complaint against $BMY Bristol employee charged with stealing trade secrets to start a rival drug firm
BMY
I'm not a techie. But fed complaint says Bristol guy was loading confidential $BMY docs onto removable external hard drives from his laptop.
BMY
Bristol $BMY guy charged w/stealing co secrets was said 2 b planning to start a drug co called "Cherish Bio Sciences" in India w/h
BMY
Alleged stolen $BMY docs from E. Syracuse plant incl part of recipe for a biologic, how 2 handle FDA inspection & investigate bad sample
BMY
Reading feds' criminal complaint against $BMY Bristol employee charged with stealing trade secrets to start a rival drug firm in India.
BMY
RT @mhuckman: US Atty charges Syracuse man w stealing trade secrets from employer Bristol-Myers Squibb $BMY to try to start a drug co in his
BMY
US Atty says guy worked in Bristol tech ops & stole "numerous trade secrets" from '07 until he was fired yesterday. $BMY
BMY
RT @mhuckman: Separately, Bristol-Myers Squibb says no pay raises this year. $BMY
BMY
Separately, Bristol-Myers Squibb says no pay raises this year. $BMY
BMY
RT @mhuckman: US Atty charges Syracuse man w stealing trade secrets from employer $BMY to try to start a drug co in his native India.
BMY
US Atty charges Syracuse man w stealing trade secrets from employer Bristol-Myers Squibb $BMY to try to start a drug co in his native India.
BMY
$BMY (Bristol-Myers Squibb) $24.75 crossed its 1st Pivot Point Resistance #emppv #stocks
http://empirasign.com/l/a2m.htm
BMY
RT @bradfranklin - RT @mhuckman: Barron's: On the NYSE Bristol-Myers Squibb $BMY had biggest short interest fall. Down 30%.
BMY
RT @mhuckman: Barron's: On the NYSE Bristol-Myers Squibb $BMY had biggest short interest fall. Down 30%.
BMY
Barron's: On the NYSE Bristol-Myers Squibb $BMY had biggest short interest fall. Down 30%.
Bristol-Myers Squibb Co. - BMY Insiders
No Insiders
We have no insiders for Bristol-Myers Squibb right now.
Know someone who is an insider on Bristol-Myers Squibb Co.?
Let us know.
Bristol-Myers Squibb Co. - BMY information
Bristol-Myers Squibb Company (BMS) engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of pharmaceuticals and nutritional products worldwide. It operates in two segments, Pharmaceuticals and Nutritionals. The Pharmaceuticals segment offers cardiovascular products, including PLAVIX, AVAPRO/AVALIDE, and PRAVACHOL; virology products comprising REYATAZ, SUSTIVA, and BARACLUDE; oncology products comprising ERBITUX, TAXOL, SPRYCEL, and IXEMPRA; affective and other psychiatric disorder products, such as ABILIFY; immunoscience products comprising ORENCIA; and other pharmaceutical products that include EFFERALGAN, ASPIRINE UPSA, DAFALGAN, and FERVEX. It sells its pharmaceutical products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The Nutritionals segment manufactures, markets, distributes, and sells infant formulas and other nutritional products comprising ENFAMIL products that contain nutrients, such as docosahexaenoic and arachidonic acids. The company is also developing various compounds, which are in phase III clinical trials, including Apixaban, Saxagliptin, Dapagliflozin, Ipilimumab, Belatacept, XL-184, Tanespimycin, and Brivanib. In addition, it develops a therapeutic class of biologics called ADNECTINS. BMS has agreements with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; ImClone Systems Incorporated; Gilead Sciences, Inc.; Medarex, Inc.; and AstraZeneca PLC, as well as collaborations with Pfizer Inc.; Exelixis, Inc.; and KineMed Inc. It also has an agreement with PDL BioPharma, Inc. for the development and commercialization of anti-CS1 antibody and elotuzumab for multiple myeloma; and a strategic alliance with Ensemble Discovery Corporation. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York....
www.bms.com
28,000 Employees
Founded in 1887
BRISTOL-MYERS SQUIBB CO (BMY:NYSE)
LAST $25.43 USD
CHANGE TODAY +0.23 0.91%
VOLUME 2.2M
As of 10:22 AM 03/10/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of BRISTOL-MYERS SQUIBB CO (BMY)
|
OPEN
$25.09
|
PREVIOUS CLOSE
$25.20
|
|
|
DAY HIGH
$25.50
|
DAY LOW
$25.08
|
|
|
52 WEEK HIGH
12/21/09 - $26.62
|
52 WEEK LOW
04/29/09 - $18.83
|
|
|
MARKET CAP
43.6B
|
AVERAGE VOLUME 10 D
11.9M
|
|
|
EPS TTM
$1.96
|
SHARES OUTSTANDING
1.7B
|
|
|
EX-DATE
03/30/10
|
P/E TTM
13.0x
|
|
|
DIVIDEND
$1.28
|
DIVIDEND YIELD
4.97%
|
|
| K = Thousands M = Millions B = Billions | ||
related news
*Final Glance: Pharmaceuticals companies
AP Digital - 03/09/2010 5:58 PM ET
Bristol-Myers CEO's 2009 compensation down 22 pct
AP Digital - 03/09/2010 5:42 PM ET
Midday Glance: Pharmaceuticals companies
AP Digital - 03/09/2010 1:21 PM ET
Early Glance: Pharmaceuticals companies
AP Digital - 03/09/2010 10:33 AM ET
*Exelixis says it will cut 270 jobs and restructure
AP Digital - 03/09/2010 7:33 AM ET
Key developments for BRISTOL-MYERS SQUIBB CO (BMY)
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (Savor-Timi 53)
03/9/2010
Bristol-Myers Squibb Company and AstraZeneca plc announced the commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus trial (SAVOR-TIMI 53), a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA(TM) (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors. The five-year study will follow approximately 12,000 patients with type 2 diabetes, who have either a history of previous cardiovascular events or multiple risk factors for vascular disease, and includes patients with renal impairment. The objectives of the SAVOR-TIMI 53 trial are to test the hypothesis of whether treatment with ONGLYZA compared with placebo when added to a patients' current standard of care will result in a reduction in the composite endpoint of cardiovascular death, non-fatal myocardial infarction or non-fatal ischaemic stroke and to exclude an unacceptable cardiovascular toxicity. The SAVOR-TIMI 53 trial was in part designed to fulfill a post-marketing requirement for the U.S. Food and Drug Administration (FDA), as well as to help answer the important question of potential benefit beyond glucose lowering. There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with ONGLYZA or any other antidiabetic drug.
Bristol-Myers Squibb Company Presents at 4th Annual Global Clinical Trial Partnerships: Optimizing Cross-Border Outsourcing Conference, Mar-01-2010 through Mar-02-2010
02/25/2010
Bristol-Myers Squibb Company Presents at 4th Annual Global Clinical Trial Partnerships: Optimizing Cross-Border Outsourcing Conference, Mar-01-2010 through Mar-02-2010. Venue: HYATT REGENCY PRINCETON, PRINCETON, New Jersey, United States.
Bristol-Myers Squibb Company Presents at Electronic Data in Clinical Trials: Collecting and Leveraging Data to Optimize Clinical Trials, Mar-09-2010
02/25/2010
Bristol-Myers Squibb Company Presents at Electronic Data in Clinical Trials: Collecting and Leveraging Data to Optimize Clinical Trials, Mar-09-2010. Venue: Crowne Plaza Philadelphia Downtown, 1800 Market Street, Philadelphia, PA 19103, United States. Speakers: Darlene Kalinowski, Associate Director, EDC Operations.
BMY Competitors
| Company | Last | Change |
| 3M Co | $81.82 USD | -0.17 |
| Amgen Inc | $57.70 USD | -0.06 |
| Eli Lilly & Co | $35.30 USD | +0.24 |
| Takeda Pharmaceutical Co Ltd | ¥4,025 JPY | +5.00 |
| Teva Pharmaceutical Industries Ltd | $61.27 USD | -0.21 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | BMY | Industry Range |
| Price/Earnings | 16.0x |
|
| Price/Sales | 2.6x |
|
| Price/Book | 2.9x |
|
| Price/Cash Flow | 4.1x |
|
| TEV/Sales | 1.5x |
|
|
BMY |
||
|
BMY transactions
| Type Date |
Target |
|
Merger/Acquisition
February 4, 2010 |
Bristol-Myers Squibb Company, Production Site in Meymac |
|
Spin-Off/Split-Off
November 15, 2009 |
Mead Johnson Nutrition Company |
|
Merger/Acquisition
November 10, 2009 |
Alder Biopharmaceuticals Inc., ALD518 |
Bristol-Myers Squibb Co. - BMY news
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53)
2010-03-10 05:33:45
Quote: There have been noclinical studies establishing conclusive evidence of macrovascular riskreduction with ONGLYZA or any other antidiabetic drug.Jerusalem, will serve as principal investigators and conduct thetrial for Bristol-Myers Squibb and AstraZeneca."One of the objectives of the SAVOR-TIMI 53 study is to test superiorityof treatment with ONGLYZA versus placebo when added to current therapy,as well as exclude unacceptable cardiovascular risk," said EugeneBraunwald, M.D., Chairman of the TIMI ...Read article
Bristol-Myers CEO's 2009 compensation down 22 pct
2010-03-10 05:33:43
Quote: (AP) -- The chief executive of drugmaker Bristol-Myers Squibb Co., James Cornelius, received a 2009 compensation package valued by The Associated Press at $17 million, down 22 percent from 2008, due to the much lower value of his stock awards.The maker of blood thinner Plavix, schizophrenia treatment Abilify and HIV drugs Reyataz and Sustiva gave Cornelius a salary of $1.5 million, up just $12,000 from the year before.The company announced last week that Cornelius is retiring on May 4 after 3 1/...Read article
BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib
2010-03-09 04:56:19
Quote: Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
(b) On March 2, 2010, Bristol-Myers Squibb Company (the "Company"), announced the
retirement of James M. Cornelius as Chief Executive Officer, effective May 4,
2010. He will remain Chairman of the Board of Directors.
(c) (1) On March 2, 2010, the Company announced that Lamberto Andreotti,
President and Chief Operating Officer of the Compan...Read article
A look at key Bristol-Myers drugs in late testing
2010-03-05 03:48:30
Quote: Some key experimental drugs in late-stage testing by biopharmaceutical company Bristol-Myers Squibb Co.:--ipilimumuab, for melanoma, the most dangerous type of skin cancer. Data from a late-stage study could be presented at a major cancer meeting in June; the company will soon seek regulatory approval for use in patients previously treated for the cancer. The company also will start a late-stage study of the drug for non-small cell lung cancer.--apixiban, for preventing life-threatening blood cl...Read article
Bristol-Myers Expects Strong 2013
2010-03-05 03:48:29
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, Andrea Tse ,Drugs
Quote: NEW YORK (TheStreet) -- Pharmaceutical company Bristol-Myers Squibb(BMY) expects non-GAAP earnings of at least $1.95 a share for 2013, saying that it is "well-positioned to deliver on the promise of our pipeline."Bristol-Myers Squibb also expects 2013 to be the first full year of impact from the loss of its Plavix patent exclusivity in the U.S., it said in a statement. However, the company expects to sustain growth in 2014 and beyond.The 2013 figure excludes any potential impact of U.S. healthca...Read article
ADVANCE-2 Study Results Demonstrate Investigational Anticoagulant Apixaban Was Statistically Superior To Enoxaparin In The Prevention Of Venous Thromboembolism Following Knee Replacement Surgery
2010-03-05 03:48:29
Quote: Read article
[$$] Bristol Sees Post-Plavix Hit
2010-03-05 03:48:28
Quote: BY PETER LOFTUS NEW YORK—Bristol-Myers Squibb Co. sees its 2013 earnings about 9% to 13% lower than anticipated 2010 levels due to the expected loss of market exclusivity for its top-selling anti-clotting drug Plavix. Bristol also said Thursday it expects to launch five new drugs by 2012, subject to regulatory approval—a prospect the drug maker is banking on to help offset the loss of patent protection for Plavix and other drugs. The experimental drugs include treatments for cancer...Read article
ExonHit to get over $36 mln from Allergan-BMS deal
2010-03-04 01:32:29
Keywords: Western Europe,Europe,France,Biotechnology,United States of America,Pharmaceuticals (sub-industry),Healthcare,Company News item,Economic news, EC, business/financial pages,
Quote: partner Allergan (AGN.N)
and Bristol-Myers Squibb (BMY.N), it said on Wednesday. The French biotechnology group would receive an upfront
payment of $4 million and an additional amount which could
exceed $32 million, together with unspecified royalties on
product sales.EHT/AGN 0001 is an oral treatment that can relieve the
symptoms of neuropathic pain. It was discovered as part of a
collaboration between Allergan and ExonHit, originally stemming
from ExonHit's laboratories.David Holmes)......Read article
Biotech Stocks: Medivation, Pfizer fall on Alzheimer's study
2010-03-04 01:32:28
Keywords: Markets|U.S. & Canada, MDVN, Medivation Inc, PFE, Pfizer Inc, DRG, Nyse Arca Pharmaceutical, BTK, Nyse Arca Biotechnology Inde, BMY, Bristol-Myers Squibb Co, AGN, Allergan Inc
Quote: stocks in focusToday's biggest advancing, declining stocksSign up for free, breaking-news email alertsEquities by SectorTechnology stocksEnergy stocksMetals stocksRetail stocksFinancialsAirline stocksPharmaand BiotechMore on MarketsBond ReportOil NewsEarningsWatchCurrenciesMarketDataEconomic CalendarSeeall the latest markets video/conga/story/misc/markets.html55637The NYSE Arca Pharmaceutical Index/quotes/comstock/10t!drg.x(DRG303.34,-0.77,-0.25%) was down nominally at 303.38 as the NYSE Arca Bi...Read article
Bristol-Myers, Allergan in $413M pain drug deal
2010-03-04 01:32:28
Quote: NEW YORK (AP) -- Bristol-Myers Squibb and Allergan will jointly attempt to develop a drug to treat chronic pain from tissue damage, the drugmakers said Wednesday.The agreement could eventually be worth $413 million, plus royalty payments.Bristol-Myers will pay Allergan $40 million up front for the rights to the drug, which is currently referred to as AGN-209323.Allergan could get another $373 million if the product advances through clinical development and regulatory review. Should the drug be a...Read article
Biotech Stocks: Medivation, CombinatoRx fall after product news
2010-03-04 01:32:26
Keywords: Markets|U.S. & Canada, MDVN, Medivation Inc, PFE, Pfizer Inc, DRG, Nyse Arca Pharmaceutical, BTK, Nyse Arca Biotechnology Inde, BMY, Bristol-Myers Squibb Co, AGN, Allergan Inc
Quote: stocks in focusToday's biggest advancing, declining stocksSign up for free, breaking-news email alertsEquities by SectorTechnology stocksEnergy stocksMetals stocksRetail stocksFinancialsAirline stocksPharmaand BiotechMore on MarketsBond ReportOil NewsEarningsWatchCurrenciesMarketDataEconomic CalendarSeeall the latest markets video/conga/story/misc/markets.html55637The NYSE Arca Pharmaceutical Index/quotes/comstock/10t!drg.x(DRG303.34,-0.77,-0.25%) was down nominally at 303.38 as the NYSE Arca Bi...Read article
Sector Snap: Drug Developers
2010-03-04 01:32:26
Quote: said Wednesday that their experimental Alzheimer's disease drug, Dimebon, failed to meet its primary and secondary goals.Bristol-Myers Squibb Co., also based in New York, fell 40 cents to $24.32. Elsewhere, shares of Merck & Co., based in Whitehouse Station, N.J., slipped 15 cents to $37.24 and shares of Swiss drug developer Novartis AG rose 2 cents to $54.28.Overall, the American Stock Exchange's pharmaceutical index, which includes some of the largest drug developers, fell less than 1 poin...Read article
Bristol-Myers Squibb to Replace CEO
2010-03-03 08:33:07
Keywords: Bristol-Myers Squibb to Replace CEO, James Cornelius, Lamberto Andreotti, BMY, Bristol-Myers Squibb
Quote: Bristol-Myers Squibb Co. (BMY) announced Tuesday that itsJames Cornelius, the company’s four-year chief executive officer will retire in May, at the age of 66.The pharmaceutical giant said its President and Chief Operating Officer, Lamberto Andreotti, 59, who also sits on the company’sboard of directors, will replace the Cornelius in the position."I have a high level of confidence in Lamberto and that is shared by everyone who has seen him consistently and successfullydrive perform...Read article
Bristol-Myers Taps Andreotti as New CEO
2010-03-03 08:33:05
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, Joseph Woelfel ,Drugs
Quote: Read article
Bristol-Myers Taps Andreotti as Next CEO
2010-03-03 08:33:05
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, Joseph Woelfel ,Drugs
Quote: Read article
Bristol-Myers Squibb and Allergan Enter Global Agreement on Investigational Neuropathic Pain Medicine
2010-03-03 08:33:04
Quote: Bristol-MyersSquibb CompanyBMYNews) and Allergan,Inc.AGNNews) today announced a global agreement for thedevelopment and commercialization of AGN-209323, a Phase II-ready,orally administered small molecule in clinical development forneuropathic pain.Under the terms of the agreement, Allergan will grant toBristol-Myers Squibb exclusive worldwide rights to develop, manufactureand commercialize AGN-209323 and backup compounds. The agreementencompasses all potential indications except ophthalmology i...Read article
Management Shuffle at Bristol-Myers
2010-03-03 08:33:04
Keywords: Mergers & Acquisitions, Investment Banking, I PO, I.P.O.s, IPOs, Offerings, Private Equity, Hedge Funds, Venture Capital, Legal, The New York Times, Andrew Ross Sorkin, Andrew Sorkin, DealBook, deal maker, Wall street, wall st., Goldman Sachs, Goldman Sa
Quote: The drug maker Bristol-Myers Squibb said on Tuesday that its chief executive would retire in May and be succeeded by the chief operating officer.
The present chief executive, James M. Cornelius, 66, will remain as chairman at the request of the company’s board, The Associated Press said. He will be succeeded as chief executive by Lamberto Andreotti, 59.
Mr. Andreotti was named president and chief operating officer in March 2009, and has been at Bristol-Myers for a dozen years, both overse...Read article
Bristol-Myers Squibb Promotes President to Chief Executive
2010-03-03 08:33:04
Keywords: Appointments and Executive Changes,Bristol-Myers Squibb Co,Cornelius James M
Quote: TRENTON (AP) — The drug maker Bristol-Myers Squibb said on Tuesday that its chief executive wouldretire in May and be succeeded by the chief operating officer.will remain as chairman at the request of the company’s board. He will be succeeded as chief executive byLamberto Andreotti, 59.Pfizer. Mr. Cornelius will retireMay 4, 2010. He became chief executive in April 2007, after serving on an interim basis about eight months. He was named chairman in February 2008.During his time at the...Read article
Stock Picks: Bristol-Myers, Qualcomm, Dish Network, Kimberly-Clark
2010-03-03 08:33:03
Keywords: Bristol-Myers Squibb, Qualcomm, Dish Network, Kimberly-Clark, stock picks, stock recommendations, analyst picks
Quote: Stock Picks: Bristol-Myers, Qualcomm, Dish Network, Kimberly-ClarkWall Street analyst opinions on stocks making headlines in Tuesday's market
Bristol-Myers Squibb Co.:BMY) on Mar. 2.
experimental drug belatacept should be allowed on the market. The outside panel voted 13-5 that the Food and Drug Administration approve the drug for the prevention of kidney transplant rejection because the benefits of the medicine outweigh the risks when compared with the older generic drug cyclosporine.
Butler...Read article
UPDATE - Bristol, Allergan in pact for new pain drug
2010-03-03 08:33:03
Keywords: Pharmaceuticals (sub-industry),United States of America,Pharmaceuticals - generic and speciality,Pharmaceuticals - diversified,Healthcare,Pharmaceuticals and biotechnology,Company News item,Economic news, EC, business/financial pages,
Quote: UPDATE 1-Bristol, Allergan in pact for new pain drug
* Bristol-Myers, Allergan in pact to develop new pain drug * Bristol-Myers to make initial payment of $40 mln * To pay milestone payments up to $373 mln, plus royalties CHICAGO, March 3 (Reuters) - Bristol-Myers Squibb Co
(BMY.N) and Allergan Inc (AGN.N) on Wednesday said they entered
into an agreement to develop and commercialize Allergan's
experimental drug to treat neuropathic pain. The drug, dubbed AGN-209323, is an orally administered dr...Read article